ACST
$0.22
Acasti Pharma
$.02
11.04%
ACST
Earnings Whisper ®
N/A
2nd Quarter September 2020
Consensus:  ($0.07)
Revenue:  $0.00 Mil
Thursday
Nov 12
8:30 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when ACST reports earnings?
Beat
Meet
Miss

Where is ACST's stock price going from here?
Up
Flat
Down
Stock chart of ACST
Analysts
Summary of analysts' recommendations for ACST
Score
Grade
Pivots
Resistance
$0.26
$0.24
$0.23

$0.21

Support
$0.20
$0.18
$0.17
Tweet
Growth
Description
Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R) is a medical food and currently Acasti's only commercialized product. Acasti Pharma Inc. is headquartered in Laval, Canada.
Peers
InterCeptRegeneron PharmaceuticalsBioMarin PharmaceuticalVertex PharmaceuticalsJohnson & JohnsonZoetisUltragenyx PharmaceuticalBristol-Myers SquibbCatalentMerck & Co.